ARCHIVES

Sanofi: Zaltrap Price Reflects Competing Drugs In Second-Line Metastatic Colon Cancer

This article is from The Cancer Letter archive.

Vol. 38 No. 41 | November 1, 2012

Download PDF Visit The Full Archive

Related Articles

Raub Briefs Councils On Women’s Health, Cost Containment

October 12, 1990

Compromise on 6,000 Grants Would Make NCI Payline Around 163-164: Natcher Committee Close to Markup

June 28, 1985

In Brief: Thomas King Names Special Assistant To Lombardi Center Director; John MacDonald Takes U. Ky. Job

March 30, 1984

NCAB Defends Organ Site Program, But DeVita Still Plan to Discuss It With Cancer Panel

October 17, 1980

CCI Gets Qualified Approval To Continue

January 18, 1980

Clinical Trials: “Master Protocol” To Rely On Biomarkers In Testing Multiple Lung Cancer Agents

November 15, 2013